EYEGATE PHARMACEUTICALS INC EYEG Cash Flow

Eyegate pharmaceuticals inc (EYEG)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14
Operating Activities:
Net (Loss) Income
-1,952	-2,701	-3,428	-1,837	870	-2,528	-3,123	-2,780	-2,379	-2,831	-4,140	-3,326	-2,919	-	-	-	-	-	-	-	-	-	-	-	-
Net Loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-3,701	-3,376	-3,823	-2,442	-2,689	-1,355	-1,541	-2,801	-351	350	-646	-902
Adjustments to Reconcile Net (Loss) Income to Net Cash Used in Operating Activities:
Depreciation and Amortization of Intangible Assets
7	12	12	12	12	12	9	7	7	5	4	4	4	4	0	0	0	0	0	0	0	0	0	0	0
Reduction of Right-of-Use Assets
41	-	-	-	39	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of Right-of-Use Assets
-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-Cash Interest Expense Charge on Beneficial Conversion Feature of Notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-1,663	0	0	0	0
Non-Cash Interest Expense Related to Debt Discount
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	244	-	-	-	-
Fair value adjustment on common stock warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-881	5	0
Stock-Based Compensation
145	203	179	236	232	254	329	145	145	169	188	235	276	120	153	124	113	79	369	290	484	1	1	1	22
Expiration of Prepaid Agreement
159	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fair Value Adjustment on Common Stock Warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-223	-	-	-	-
Loss on Cancellation of Stockholder Note Receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-200
Changes in Operating Assets and Liabilities:
License and Grant Receivable
-	-	-	-	-	-	-	-	-	-601	455	4,036	-3,927	-855	-1,517	-291	-570	1,907	-1,000	0	0	-	-	-	-
Prepaid Expenses and Other Current Assets
67	-69	-23	-147	243	-413	48	-116	102	253	-159	-44	398	-62	-107	-114	257	38	-49	-46	154	10	-7	5	-4
Refundable Tax Credit Receivable
0	0	3	-5	-11	1	4	-11	1	1	3	-0	0	2	-11	1	0	3	-0	-1	0	1	-42	31	2
Other Assets
11	46	0	0	-8	-49	-19	0	0	-0	0	0	0	1	8	-1	7	1	0	0	-0	0	0	-24	25
Accounts Payable
-52	-857	971	-147	180	-260	-31	134	-484	47	-312	-340	-101	7	171	360	173	259	-179	51	-279	290	46	221	-5
Lease Liabilities
41	41	40	40	38	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue
0	0	0	0	-2,686	0	-37	669	-92	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unbilled Revenue
-	-	-	-	-	0	0	-116	806	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue
-	-	-	-	-	-	-	-	-	-	-	4,636	0	-48	-607	-142	798	1,907	0	0	0	-	-	-	-
Unbilled Revenue
-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Accrued Expenses
-629	137	246	161	-535	-31	106	-366	-402	91	557	303	-808	651	-301	401	-300	844	-54	178	-703	-47	305	362	276
Net Cash Used in Operating Activities
-2,400	-2,586	-1,998	-1,422	-2,146	-2,003	-2,781	-1,945	-4,114	-1,453	-2,518	-2,478	-18	-	-	-	-	-	-	-	-	-	-	-	-
Investing Activities:
Restricted Cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	15	10	0	0	0	20	-	-	-	-
Net Cash Used in Operating Activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2,675	-1,353	-1,548	-169	-972	-1,768	-436	-30	-53	-431
Acquisition of Jade (Net of Cash Acquired)
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	185	0	0	0	0	-	-	-	-
Financing Activities:
Net Cash Provided by Investing Activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-15	175	0	0	0	-20	-	-	-	-
Proceeds from Initial Public Stock Offering
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	4,099	0	0	0	0
Proceeds from Stock Offerings, Net of Offering Costs
4,501	1,777	0	0	0	-	-	-	-	0	0	8,666	1,922	0	-0	3,768	0	-	-	-	-	-	-	-	-
Proceeds from convertible notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	284	538	486	446
Exercise of Common Stock Options
-	-	-	-	-	-	-	-	-	0	0	38	1	0	0	56	0	8	3	0	14	0	6	0	0
Stock Issuance Costs
-	-	-	-	-	-	-	-	40	-	-	-	98	0	0	323	0	-	-	-	-	-	-	-	-
Offering Costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	1,185	68	224	-40	648	540	0
Equipment Financing Payments
0	0	1	1	1	1	1	3	3	3	3	3	3	2	0	0	0	-	-	-	-	-	-	-	-
Net Cash Provided by (Used in) Financing Activities
4,501	3,907	-15	30	-1	110	338	10,900	-43	50	-3	8,800	1,822	-	-	-	-	-	-	-	-	-	-	-	-
Payments of Grants Payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0
Grant Refund
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	32	-	-	-	-
Net Cash Provided by Financing Activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,501	0	8	8,819	-68	3,856	324	-103	-54	446
Effect of Exchange Rate Changes on Cash
-	-	-	-	-	-	-	-	0	0	2	3	-1	7	0	0	-1	15	-4	29	50	-32	42	-14	7
Effect of Exchange Rate Changes on Cash
0	-	3	1	-0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Increase (Decrease) in Cash
2,101	-	-2,010	-1,390	-2,148	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Decrease in Cash
-	-	-	-	-	-	-	-	-4,157	-1,438	-2,518	6,325	1,802	-2,022	-2,344	811	-1,179	-1,525	8,645	-1,011	2,118	-144	-90	-121	22
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Cash paid for income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Supplemental Disclosures of Noncash Operating and Financing Activities
Creation of Right-of-Use Assets and Related Lease Liabilities
-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Conversion of Non-Controlling Interests to Common Stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	6,818	0	0	0	0
Creation of Right-of-Use Assets and Related Lease Liabilities
102	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	36,408	0	0	0	0
Cancellation of Restricted Stock
0	0	-35	35	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Grant of Restricted Stock Awards
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Exercise of Common Warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0
Conversion of Promissory Notes and Accrued Interest into Common Stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	3,532	0	0	0	0
Deemed Dividend on Conversion of Preferred Stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	8,222	-	-	-	-
Application of Deferred Offering Costs on IPO
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	1,148	-	-	-	-
Warrant Liability Reclassified to Stockholders Equity
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	79	-	-	-	-
Issuance of Common Stock to Acquire Jade Therapeutics, Inc.
-	-	-	-	-	-	-	-	-	-	-	-	-	0	439	27	2,442	0	0	0	0	-	-	-	-
Contingent Liability in Connection with Jade Acquisition
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	1,210	0	0	0	0	-	-	-	-
ASU 2016-02
Creation of Right-of-Use Assets and Related Lease Liabilities
0	-	-	-	136	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-